MX2012007052A - Metodo para tratar fibrilacion atrial. - Google Patents

Metodo para tratar fibrilacion atrial.

Info

Publication number
MX2012007052A
MX2012007052A MX2012007052A MX2012007052A MX2012007052A MX 2012007052 A MX2012007052 A MX 2012007052A MX 2012007052 A MX2012007052 A MX 2012007052A MX 2012007052 A MX2012007052 A MX 2012007052A MX 2012007052 A MX2012007052 A MX 2012007052A
Authority
MX
Mexico
Prior art keywords
atrial fibrillation
treating atrial
salts
atrial
pharmaceutically acceptable
Prior art date
Application number
MX2012007052A
Other languages
English (en)
Inventor
Charles Antzelevitch
Luiz Belardinelli
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43736345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012007052(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2012007052A publication Critical patent/MX2012007052A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

La presente invención se refiere a un método para el tratamiento o prevención de fibrilación atrial y/o flúter atrial, en donde el método comprende la coadministración de una cantidad sinérgicamente terapéutica de dronedarona o una sal o sales farmacéuticamente aceptables de la misma, y una cantidad sinérgicamente terapéutica de ranolazina o una sal o sales farmacéuticamente aceptables de la misma. También se proporcionan métodos para modular el rango y ritmo ventricular y atrial. La presente invención también se refiere a formulaciones farmacéuticas que son adecuadas para dicha administración combinada.
MX2012007052A 2009-12-21 2010-12-20 Metodo para tratar fibrilacion atrial. MX2012007052A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28873909P 2009-12-21 2009-12-21
PCT/US2010/061257 WO2011084733A1 (en) 2009-12-21 2010-12-20 Method of treating atrial fibrillation

Publications (1)

Publication Number Publication Date
MX2012007052A true MX2012007052A (es) 2012-07-30

Family

ID=43736345

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012007052A MX2012007052A (es) 2009-12-21 2010-12-20 Metodo para tratar fibrilacion atrial.
MX2014002642A MX344329B (es) 2009-12-21 2010-12-20 Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014002642A MX344329B (es) 2009-12-21 2010-12-20 Formulación de una combinación de dronedarona y ranolazina para la manufactura de un medicamento para tratar fibrilación atrial.

Country Status (37)

Country Link
US (3) US8513254B2 (es)
EP (2) EP2515900B1 (es)
JP (2) JP5723889B2 (es)
KR (2) KR20120107995A (es)
CN (3) CN102665713B (es)
AP (1) AP3536A (es)
AR (1) AR079552A1 (es)
AU (1) AU2010339753B2 (es)
BR (1) BR112012015499A2 (es)
CA (1) CA2784028C (es)
CL (1) CL2012001597A1 (es)
CR (1) CR20120353A (es)
CY (1) CY1116511T1 (es)
DK (1) DK2515900T3 (es)
EA (2) EA201691336A1 (es)
EC (1) ECSP12012004A (es)
ES (2) ES2646603T3 (es)
HK (1) HK1170675A1 (es)
HR (1) HRP20150644T1 (es)
HU (1) HUE026916T2 (es)
IL (1) IL220152A (es)
ME (1) ME02179B (es)
MX (2) MX2012007052A (es)
NO (1) NO2749282T3 (es)
NZ (2) NZ600718A (es)
PE (1) PE20121520A1 (es)
PL (2) PL2749282T3 (es)
PT (2) PT2749282T (es)
RS (1) RS54118B1 (es)
SG (3) SG10201710751TA (es)
SI (2) SI2749282T1 (es)
SM (1) SMT201500171B (es)
TW (1) TWI508726B (es)
UA (1) UA109887C2 (es)
UY (1) UY33119A (es)
WO (1) WO2011084733A1 (es)
ZA (1) ZA201204608B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011530A (es) 2002-05-21 2005-08-15 Cv Therapeutics Inc Administracion de un inhibidor de acido graso parcial tal como ranolazina para el tratamiento de diabetes.
CA2774715C (en) 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104873389B (zh) 2009-07-29 2017-12-05 Icu医学有限公司 流体传输装置及使用方法
WO2011135582A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of dronedarone
CA2802288C (en) 2010-07-02 2018-08-21 Gilead Sciences, Inc. Triazolopyridinone compounds as ion channel modulators
KR20140033377A (ko) 2011-05-10 2014-03-18 길리애드 사이언시즈, 인코포레이티드 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
TWI549944B (zh) 2011-07-01 2016-09-21 吉李德科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (es) 2011-07-01 2018-04-28
AU2013203252B2 (en) * 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2014179764A1 (en) * 2013-05-03 2014-11-06 Gilead Sciences, Inc. Method of treating atrial fibrillation
JP6141580B2 (ja) * 2013-08-02 2017-06-07 ギリアード サイエンシーズ， インコーポレイテッド ラノラジンおよびドロネダロンの医薬組成物
US9932588B2 (en) * 2013-11-15 2018-04-03 Northwestern University Inhibition of oxidative stress in atrial fibrillation
WO2015095370A1 (en) 2013-12-19 2015-06-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CN104951870B (zh) * 2015-06-01 2018-11-13 南通科瑞斯生物医药科技有限公司 药物临床前心脏风险评估方法
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
EP3423057A1 (en) 2016-03-04 2019-01-09 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
US10575744B2 (en) 2017-02-24 2020-03-03 Medtronic Cryocath Lp Pericardial balloon mapping
US10799703B2 (en) * 2017-12-22 2020-10-13 Medtronic, Inc. Evaluation of his bundle pacing therapy
EP3530182B1 (en) * 2018-02-27 2020-12-09 Nokia Technologies Oy Apparatus and method for determining a change in left ventricular twist of a subject's heart
JP2022518765A (ja) * 2019-01-24 2022-03-16 ノースウエスタン ユニバーシティ 心房細動の遺伝子療法による治療

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP0407780B1 (en) 1989-06-23 1996-09-11 Syntex (U.S.A.) Inc. Ranolazine and related piperazines used in the treatment of tissues experiencing a physical or chemical insult
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
FR2764800B1 (fr) 1997-06-23 1999-09-10 Sanofi Sa Composition pharmaceutique solide contenant des derives de benzofuranne
US6303607B1 (en) 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
AU7804501A (en) * 2000-07-27 2002-02-13 Pharmacia Corp Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
FR2817750B1 (fr) 2000-12-11 2003-02-21 Sanofi Synthelabo Composition pharmaceutique de dronedarone pour administration parenterale
US7022343B2 (en) 2000-12-27 2006-04-04 Genzyme Corporation Controlled release of anti-arrhythmic agents
CA2453587A1 (en) * 2001-07-20 2003-02-06 Karo Bio Ab Benzofuranes and their use in the treatment of atrial fibrillation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
BRPI0606403A2 (pt) 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP2117509A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
EP2133074A1 (en) * 2008-06-10 2009-12-16 Sanofi-Aventis Use of dronedarone for the preparation of a medicament intended for the prevention of permanent atrial fibrillation
EP2337559A2 (en) 2008-09-04 2011-06-29 Gilead Sciences, Inc. Method of treating atrial fibrillation

Also Published As

Publication number Publication date
CL2012001597A1 (es) 2013-06-28
AR079552A1 (es) 2012-02-01
CN102665713A (zh) 2012-09-12
US20110183990A1 (en) 2011-07-28
HUE026916T2 (en) 2016-08-29
CR20120353A (es) 2014-10-07
CY1116511T1 (el) 2017-03-15
US20140323493A1 (en) 2014-10-30
PT2515900E (pt) 2015-07-30
JP5723889B2 (ja) 2015-05-27
EP2515900B1 (en) 2015-04-29
US8754087B2 (en) 2014-06-17
PL2515900T3 (pl) 2015-10-30
SI2515900T1 (sl) 2015-07-31
US20130317038A1 (en) 2013-11-28
ECSP12012004A (es) 2012-08-31
EA201691336A1 (ru) 2017-05-31
IL220152A0 (en) 2012-07-31
HK1170675A1 (en) 2013-03-08
KR20120107995A (ko) 2012-10-04
EP2515900A1 (en) 2012-10-31
DK2515900T3 (en) 2015-07-27
CA2784028C (en) 2016-08-23
IL220152A (en) 2016-11-30
PT2749282T (pt) 2017-11-15
AU2010339753A1 (en) 2012-07-12
BR112012015499A2 (pt) 2016-05-03
AP2012006331A0 (en) 2012-06-30
NZ627181A (en) 2016-02-26
TWI508726B (zh) 2015-11-21
US8513254B2 (en) 2013-08-20
KR20160108611A (ko) 2016-09-19
NZ600718A (en) 2014-08-29
TW201136586A (en) 2011-11-01
SI2749282T1 (sl) 2017-12-29
RS54118B1 (en) 2015-12-31
EA201290451A1 (ru) 2013-01-30
CN104688739A (zh) 2015-06-10
EP2749282A1 (en) 2014-07-02
JP2015057449A (ja) 2015-03-26
MX344329B (es) 2016-12-13
WO2011084733A1 (en) 2011-07-14
PL2749282T3 (pl) 2018-01-31
ME02179B (me) 2015-10-20
SG10201408528RA (en) 2015-04-29
CA2784028A1 (en) 2011-07-14
AU2010339753B2 (en) 2015-01-22
SG10201710751TA (en) 2018-02-27
PE20121520A1 (es) 2012-11-26
UY33119A (es) 2011-07-29
ES2540093T3 (es) 2015-07-08
AP3536A (en) 2016-01-13
US9056108B2 (en) 2015-06-16
SMT201500171B (it) 2015-09-07
ZA201204608B (en) 2013-02-27
HRP20150644T1 (hr) 2015-07-31
CN104147010A (zh) 2014-11-19
UA109887C2 (uk) 2015-10-26
CN102665713B (zh) 2015-02-18
NO2749282T3 (es) 2018-01-06
EP2749282B1 (en) 2017-08-09
EA025445B1 (ru) 2016-12-30
SG181541A1 (en) 2012-07-30
ES2646603T3 (es) 2017-12-14
JP2013515007A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
MX2012007052A (es) Metodo para tratar fibrilacion atrial.
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
PH12017501939B1 (en) 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
MX2018001487A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6 y la composición farmacéutica que comprende los mismos.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
WO2010028173A3 (en) Method of treating atrial fibrillation
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX2019012884A (es) Terapia de combinacion.
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
MX2012002681A (es) Agente terapeutico/profilactico que contiene pth para la osteoporosis, caracterizado porque la pth se administra una vez a la semana en una dosis unitaria de 100 a 200 unidades.
MX2019002121A (es) Tratamiento conjunto para tratar el cancer de pancreas.
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
MX2018013477A (es) Acidos carboxilicos para tratar/prevenir una enfermedad de la piel.
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
MX2022012001A (es) Tratamiento preventivo de la migra?a.
PH12015502465A1 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2018013474A (es) Acidos carboxilicos para aplicacion en la primera infancia.
WO2016178987A3 (en) Preventing or treating viral infection by inhibition of the histone methyltransferase ezh1 or ezh2

Legal Events

Date Code Title Description
FG Grant or registration